Clinical

An adult patient with pulmonary arterial hypertension (PAH) and metastatic lung adenocarcinoma showed significant clinical improvement when chemotherapy and immunotherapy were added to PAH triple therapy.

The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype to significantly help reduce exacerbations and improve lung function.

Researchers report on the long-term immune changes in patients with refractory or relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax and rituximab plus bendamustine and rituximab.

While smoking is a key risk factor for chronic obstructive pulmonary disease (COPD), significant prevalence also exists among nonsmokers, highlighting the need for broader public health strategies.

NXP800 was granted orphan drug designation from the FDA in ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.

The South Asian Healthcare Leadership Forum marked its 10th anniversary with a gathering of over 100 prominent physicians, policy makers, and executives at Brigham and Women’s Hospital.

A 3-year follow-up of patients with refractory/relapsed indolent non-Hodgkin (NHL) treated with a combination of magrolimab and rituximab showed no new treatment-emergent adverse events, suggesting long-term safety. The treatment also confirmed magrolimab penetration into the tumor.

Daratumumab plus VRd and frontline daratumumab plus VTd produced deep, durable responses in patients with transplant-eligible multiple myeloma in updates to the PERSEUS and CASSIOPEIA trials, respectively.

Speakers on precursor disease addressed distinctions between MGUS and smoldering multiple myeloma, risk stratification, and new thinking on the role of immunological aging, especially how it affects Black patients.

In the PANORAMA-HF trial, children receiving sacubitril/valsartan for their heart failure experienced clinically meaningful improvements similar to those seen in children receiving enalapril, although the former may provide an edge on quality of life.

The European Medicines Agency's (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing authorization of mirvetuximab soravtansine (Elahere; AbbVie) for folate receptor alpha–positive (FRα+), platinum-resistant epithelial ovarian cancer.

A poster presented at the Skin of Color Update reported that hidradenitis suppurativa (HS) disproportionately affects Black patients, women, smokers, and those with public insurance or disabilities.

Medical experts discuss how to frame the conversation with patients about third-line metastatic colorectal cancer treatment selection, balancing efficacy, safety, and overall prognosis.

A study based on a decade's worth of Korean insurance data found that use of direct oral anticoagulants (DOACs) to address atrial fibrillation and venous thromboembolism in patients with myeloproliferative neoplasms (MPNs) is effective, with acceptable bleeding risk.

Panelists discuss how biomarkers of type 2 inflammation, such as blood eosinophils, serum IgE, and fractional exhaled nitric oxide, can aid in diagnosing and monitoring type 2 inflammatory diseases as well as in predicting treatment response.

Treatment with maintenance olaparib/cediranib demonstrated similar survival vs olaparib alone in platinum-sensitive relapsed ovarian cancer.

Boarding times in the emergency department (ED) have risen nationally, but the implications for health equity have remained understudied. This study investigated whether prolonged ED boarding contributed to perceived racial discrimination and dissatisfaction with care.

New research shows how repetitive nerve stimulation and single fiber electromyography can help diagnose disorders such as myasthenia gravis.

Multiple sessions at ESMO Congress 2024 covered antibody-drug conjugates (ADCs), which are an emerging therapy that holds great promise in cancer but comes with challenges.

September 24 celebrates Familial Hypercholesterolemia Awareness Day, which recognizes the importance of screening measures, education, and advocacy in a lesser-known, underdiagnosed cardiovascular condition.

The FDA has approved FluMist (AstraZeneca) for self-administration by adults up to age 49 years or for caregiver administration for children aged 2 to 17 years, making it the first self-administered flu vaccine option.

New findings add to the understanding of the patient experience in axial spondyloarthritis (axSpA), which can help inform patient-centered clinical care.

Experts in cardiometabolic risk management examine the factors contributing to low adherence to guidelines for cardiometabolic conditions, with a specific focus on type 2 diabetes.

Key opinion leaders review current guidelines for cardiometabolic conditions, emphasizing recent advancements in the field.

The proposed Medicare High-Value Drug List Model, also known as the Medicare $2 Drug List, could have modestly reduced out-of-pocket costs for 38% of beneficiaries if implemented in 2021.

The 21st annual meeting of the International Myeloma Society (IMS) takes place September 25-28, 2024, in Rio de Janeiro, Brazil.

A recent analysis investigated the state of metabolic disruption experienced by patients with spinal muscular atrophy (SMA), adding to the literature on nutritional and metabolic complications linked to SMA.

Researchers developed a pan-immune-inflammation–based nomogram to accurately predict overall survival (OS) and progression-free survival (PFS) in patients with epithelial ovarian cancer

The phase 1/2 SAINT study is currently investigating intravenous trabectedin plus ipilimumab and nivolumab in the first line for advanced soft tissue sarcoma.

In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently diagnosed in patients with cardio-pulmonary comorbidities, which poses challenges to the optimal treatment of PAH, explained the researchers.